Bristol-Myers Squibb Company (ETR:BRM)
43.60
-0.29 (-0.65%)
Apr 17, 2025, 5:35 PM CET
ETR:BRM Revenue
In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B USD with 7.32% growth. Bristol-Myers Squibb Company had revenue of $12.34B in the quarter ending December 31, 2024, with 7.54% growth.
Revenue
$48.30B
Revenue Growth
+7.32%
P/S Ratio
1.89
Revenue / Employee
$1.42M
Employees
34,100
Market Cap
88.09B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 22.67B |
Fresenius SE & Co. KGaA | 21.83B |
Bayer Aktiengesellschaft | 46.61B |
Sartorius Aktiengesellschaft | 3.44B |
Fresenius Medical Care AG | 19.34B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
Bristol-Myers Squibb Company News
- 3 days ago - Bristol-Myers Squibb (BMY) Shares Decline Amid FDA Updates and Mixed Trial Results - GuruFocus
- 4 days ago - Bristol-Myers Squibb Co (BMY) Announces FDA Updates for CAMZYOS Prescribing Information | BMY ... - GuruFocus
- 4 days ago - U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications - Benzinga
- 4 days ago - U.S. Food and Drug Administration Updates CAMZYOS (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications - Wallstreet:Online
- 5 days ago - 2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT - Wallstreet:Online
- 6 days ago - Bristol Myers Squibb (BMY) Partners with Optellum for AI Lung Cancer Diagnosis - GuruFocus
- 6 days ago - Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch - Benzinga
- 6 days ago - Optellum partners with Bristol Myers to use AI-driven lung cancer diagnosis - Seeking Alpha